drugset / Trial / NCT04911335

Propolis-based Product (FARINGEL PLUS) for Oral Mucositis in Palliative Care

NCT04911335 ↗

Phase 2 Completed 77 enrolled Campus-Bio-Medico University
NaSingle-groupOpen-labelTreatment

Summary

Oral health is crucial for palliative patients' quality of life. The evidence on effective interventions and measures of oral mucositis in palliative care is sparse. This is a single-center, prospective, uncontrolled open label Phase 2 non-profit study, aimed at evaluating a propolis-based product (FARINGEL PLUS) added to basic oral hygiene safety, acceptability and activity in preventing and treating oral mucositis in patients in palliative care. A two-step design was adopted according to Simon's Optimum approach, with an overall sample of 77 evaluable cases (step1\_26 cases; step2\_51 cases).

Timeline

Start
2021-07-13
Primary completion
2022-11-07
Completion
2022-11-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Faringel plus Unknown 7 ml Oral

Indications